nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—Ezetimibe—atherosclerosis	0.0802	0.267	CbGbCtD
Amantadine—ABCB1—Simvastatin—atherosclerosis	0.0745	0.248	CbGbCtD
Amantadine—ABCB1—Pravastatin—atherosclerosis	0.0729	0.243	CbGbCtD
Amantadine—ABCB1—Lovastatin—atherosclerosis	0.0729	0.243	CbGbCtD
Amantadine—Libido increased—Niacin—atherosclerosis	0.00753	0.0177	CcSEcCtD
Amantadine—Hypokinesia—Niacin—atherosclerosis	0.00678	0.016	CcSEcCtD
Amantadine—Nightmare—Rosuvastatin—atherosclerosis	0.00608	0.0143	CcSEcCtD
Amantadine—Hypertonia—Rosuvastatin—atherosclerosis	0.00551	0.013	CcSEcCtD
Amantadine—Renal failure acute—Rosuvastatin—atherosclerosis	0.00495	0.0116	CcSEcCtD
Amantadine—Amnesia—Rosuvastatin—atherosclerosis	0.00486	0.0114	CcSEcCtD
Amantadine—Nightmare—Simvastatin—atherosclerosis	0.00482	0.0113	CcSEcCtD
Amantadine—Photosensitivity—Lovastatin—atherosclerosis	0.00441	0.0104	CcSEcCtD
Amantadine—Nightmare—Pravastatin—atherosclerosis	0.00435	0.0102	CcSEcCtD
Amantadine—Photosensitivity—Ezetimibe—atherosclerosis	0.00432	0.0102	CcSEcCtD
Amantadine—Photosensitivity—Simvastatin—atherosclerosis	0.00412	0.0097	CcSEcCtD
Amantadine—Amnesia—Lovastatin—atherosclerosis	0.00412	0.00969	CcSEcCtD
Amantadine—Amnesia—Ezetimibe—atherosclerosis	0.00404	0.00951	CcSEcCtD
Amantadine—Eczema—Simvastatin—atherosclerosis	0.00403	0.00948	CcSEcCtD
Amantadine—Hypertonia—Niacin—atherosclerosis	0.00401	0.00945	CcSEcCtD
Amantadine—Amnesia—Simvastatin—atherosclerosis	0.00385	0.00907	CcSEcCtD
Amantadine—Photosensitivity—Pravastatin—atherosclerosis	0.00373	0.00877	CcSEcCtD
Amantadine—Eczema—Niacin—atherosclerosis	0.0037	0.0087	CcSEcCtD
Amantadine—Renal failure acute—Pravastatin—atherosclerosis	0.00355	0.00834	CcSEcCtD
Amantadine—Liver function test abnormal—Ezetimibe—atherosclerosis	0.0035	0.00825	CcSEcCtD
Amantadine—Amnesia—Pravastatin—atherosclerosis	0.00348	0.0082	CcSEcCtD
Amantadine—Disturbance in sexual arousal—Niacin—atherosclerosis	0.0033	0.00776	CcSEcCtD
Amantadine—Urinary retention—Niacin—atherosclerosis	0.00316	0.00744	CcSEcCtD
Amantadine—Liver function test abnormal—Niacin—atherosclerosis	0.00307	0.00722	CcSEcCtD
Amantadine—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00305	0.00719	CcSEcCtD
Amantadine—Orthostatic hypotension—Niacin—atherosclerosis	0.00304	0.00714	CcSEcCtD
Amantadine—Liver function test abnormal—Pravastatin—atherosclerosis	0.00302	0.00711	CcSEcCtD
Amantadine—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00299	0.00705	CcSEcCtD
Amantadine—Dysphagia—Niacin—atherosclerosis	0.00287	0.00676	CcSEcCtD
Amantadine—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00286	0.00672	CcSEcCtD
Amantadine—Arrhythmia—Rosuvastatin—atherosclerosis	0.00282	0.00664	CcSEcCtD
Amantadine—Mental disorder—Rosuvastatin—atherosclerosis	0.00277	0.00651	CcSEcCtD
Amantadine—Sweating increased—Pravastatin—atherosclerosis	0.00276	0.00648	CcSEcCtD
Amantadine—Oedema peripheral—Ezetimibe—atherosclerosis	0.00259	0.00609	CcSEcCtD
Amantadine—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00258	0.00608	CcSEcCtD
Amantadine—Angiopathy—Ezetimibe—atherosclerosis	0.00238	0.00561	CcSEcCtD
Amantadine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00237	0.00557	CcSEcCtD
Amantadine—Alopecia—Lovastatin—atherosclerosis	0.00237	0.00557	CcSEcCtD
Amantadine—Alopecia—Ezetimibe—atherosclerosis	0.00232	0.00546	CcSEcCtD
Amantadine—Mental disorder—Ezetimibe—atherosclerosis	0.0023	0.00541	CcSEcCtD
Amantadine—Malnutrition—Ezetimibe—atherosclerosis	0.00229	0.00538	CcSEcCtD
Amantadine—Oedema peripheral—Niacin—atherosclerosis	0.00227	0.00533	CcSEcCtD
Amantadine—Confusional state—Rosuvastatin—atherosclerosis	0.00226	0.00533	CcSEcCtD
Amantadine—Visual impairment—Niacin—atherosclerosis	0.00222	0.00522	CcSEcCtD
Amantadine—Alopecia—Simvastatin—atherosclerosis	0.00221	0.00521	CcSEcCtD
Amantadine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.0022	0.00518	CcSEcCtD
Amantadine—Vision blurred—Lovastatin—atherosclerosis	0.0022	0.00517	CcSEcCtD
Amantadine—Mental disorder—Simvastatin—atherosclerosis	0.00219	0.00516	CcSEcCtD
Amantadine—Tremor—Lovastatin—atherosclerosis	0.00218	0.00514	CcSEcCtD
Amantadine—Visual impairment—Pravastatin—atherosclerosis	0.00218	0.00514	CcSEcCtD
Amantadine—Eye disorder—Niacin—atherosclerosis	0.00215	0.00506	CcSEcCtD
Amantadine—Cardiac disorder—Pravastatin—atherosclerosis	0.0021	0.00495	CcSEcCtD
Amantadine—Angiopathy—Niacin—atherosclerosis	0.00209	0.00491	CcSEcCtD
Amantadine—Leukopenia—Lovastatin—atherosclerosis	0.00209	0.00491	CcSEcCtD
Amantadine—Vision blurred—Simvastatin—atherosclerosis	0.00205	0.00484	CcSEcCtD
Amantadine—Arrhythmia—Niacin—atherosclerosis	0.00205	0.00483	CcSEcCtD
Amantadine—Tremor—Simvastatin—atherosclerosis	0.00204	0.00481	CcSEcCtD
Amantadine—Alopecia—Niacin—atherosclerosis	0.00203	0.00478	CcSEcCtD
Amantadine—Insomnia—Rosuvastatin—atherosclerosis	0.00203	0.00478	CcSEcCtD
Amantadine—Arrhythmia—Pravastatin—atherosclerosis	0.00202	0.00476	CcSEcCtD
Amantadine—Palpitations—Ezetimibe—atherosclerosis	0.00202	0.00475	CcSEcCtD
Amantadine—Paraesthesia—Rosuvastatin—atherosclerosis	0.00202	0.00474	CcSEcCtD
Amantadine—Malnutrition—Niacin—atherosclerosis	0.002	0.00471	CcSEcCtD
Amantadine—Alopecia—Pravastatin—atherosclerosis	0.002	0.00471	CcSEcCtD
Amantadine—Anxiety—Lovastatin—atherosclerosis	0.00198	0.00465	CcSEcCtD
Amantadine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00198	0.00465	CcSEcCtD
Amantadine—Hypertension—Ezetimibe—atherosclerosis	0.00197	0.00464	CcSEcCtD
Amantadine—Tension—Niacin—atherosclerosis	0.00196	0.00462	CcSEcCtD
Amantadine—Leukopenia—Simvastatin—atherosclerosis	0.00195	0.00459	CcSEcCtD
Amantadine—Nervousness—Niacin—atherosclerosis	0.00194	0.00458	CcSEcCtD
Amantadine—Dry mouth—Lovastatin—atherosclerosis	0.00194	0.00457	CcSEcCtD
Amantadine—Tension—Pravastatin—atherosclerosis	0.00193	0.00455	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00193	0.00455	CcSEcCtD
Amantadine—Constipation—Rosuvastatin—atherosclerosis	0.00192	0.00452	CcSEcCtD
Amantadine—Confusional state—Lovastatin—atherosclerosis	0.00192	0.00451	CcSEcCtD
Amantadine—Nervousness—Pravastatin—atherosclerosis	0.00191	0.00451	CcSEcCtD
Amantadine—Dry mouth—Ezetimibe—atherosclerosis	0.0019	0.00448	CcSEcCtD
Amantadine—Anaphylactic shock—Lovastatin—atherosclerosis	0.0019	0.00448	CcSEcCtD
Amantadine—Vision blurred—Niacin—atherosclerosis	0.00189	0.00444	CcSEcCtD
Amantadine—Confusional state—Ezetimibe—atherosclerosis	0.00188	0.00443	CcSEcCtD
Amantadine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00187	0.00439	CcSEcCtD
Amantadine—Vision blurred—Pravastatin—atherosclerosis	0.00186	0.00437	CcSEcCtD
Amantadine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00185	0.00435	CcSEcCtD
Amantadine—Anxiety—Simvastatin—atherosclerosis	0.00185	0.00435	CcSEcCtD
Amantadine—Tremor—Pravastatin—atherosclerosis	0.00185	0.00435	CcSEcCtD
Amantadine—Nervous system disorder—Ezetimibe—atherosclerosis	0.00183	0.00431	CcSEcCtD
Amantadine—Anorexia—Lovastatin—atherosclerosis	0.00181	0.00427	CcSEcCtD
Amantadine—Skin disorder—Ezetimibe—atherosclerosis	0.00181	0.00426	CcSEcCtD
Amantadine—Confusional state—Simvastatin—atherosclerosis	0.00179	0.00422	CcSEcCtD
Amantadine—Leukopenia—Niacin—atherosclerosis	0.00179	0.00422	CcSEcCtD
Amantadine—Anaphylactic shock—Simvastatin—atherosclerosis	0.00178	0.00419	CcSEcCtD
Amantadine—Oedema—Simvastatin—atherosclerosis	0.00178	0.00419	CcSEcCtD
Amantadine—Palpitations—Niacin—atherosclerosis	0.00177	0.00416	CcSEcCtD
Amantadine—Leukopenia—Pravastatin—atherosclerosis	0.00176	0.00415	CcSEcCtD
Amantadine—Insomnia—Lovastatin—atherosclerosis	0.00172	0.00405	CcSEcCtD
Amantadine—Paraesthesia—Lovastatin—atherosclerosis	0.00171	0.00402	CcSEcCtD
Amantadine—Hypertension—Pravastatin—atherosclerosis	0.0017	0.004	CcSEcCtD
Amantadine—Anorexia—Simvastatin—atherosclerosis	0.0017	0.00399	CcSEcCtD
Amantadine—Dyspnoea—Lovastatin—atherosclerosis	0.0017	0.00399	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00169	0.00398	CcSEcCtD
Amantadine—Insomnia—Ezetimibe—atherosclerosis	0.00169	0.00397	CcSEcCtD
Amantadine—Paraesthesia—Ezetimibe—atherosclerosis	0.00168	0.00394	CcSEcCtD
Amantadine—Dyspepsia—Lovastatin—atherosclerosis	0.00167	0.00394	CcSEcCtD
Amantadine—Anxiety—Pravastatin—atherosclerosis	0.00167	0.00394	CcSEcCtD
Amantadine—Dry mouth—Niacin—atherosclerosis	0.00167	0.00392	CcSEcCtD
Amantadine—Dyspnoea—Ezetimibe—atherosclerosis	0.00166	0.00391	CcSEcCtD
Amantadine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00165	0.00389	CcSEcCtD
Amantadine—Decreased appetite—Lovastatin—atherosclerosis	0.00165	0.00389	CcSEcCtD
Amantadine—Dyspepsia—Ezetimibe—atherosclerosis	0.00164	0.00387	CcSEcCtD
Amantadine—Fatigue—Lovastatin—atherosclerosis	0.00164	0.00386	CcSEcCtD
Amantadine—Oedema—Niacin—atherosclerosis	0.00163	0.00384	CcSEcCtD
Amantadine—Anaphylactic shock—Niacin—atherosclerosis	0.00163	0.00384	CcSEcCtD
Amantadine—Constipation—Lovastatin—atherosclerosis	0.00163	0.00383	CcSEcCtD
Amantadine—Confusional state—Pravastatin—atherosclerosis	0.00162	0.00382	CcSEcCtD
Amantadine—Decreased appetite—Ezetimibe—atherosclerosis	0.00162	0.00382	CcSEcCtD
Amantadine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00161	0.00379	CcSEcCtD
Amantadine—Asthenia—Rosuvastatin—atherosclerosis	0.00161	0.00379	CcSEcCtD
Amantadine—Insomnia—Simvastatin—atherosclerosis	0.00161	0.00379	CcSEcCtD
Amantadine—Anaphylactic shock—Pravastatin—atherosclerosis	0.00161	0.00379	CcSEcCtD
Amantadine—Oedema—Pravastatin—atherosclerosis	0.00161	0.00379	CcSEcCtD
Amantadine—Fatigue—Ezetimibe—atherosclerosis	0.00161	0.00379	CcSEcCtD
Amantadine—Paraesthesia—Simvastatin—atherosclerosis	0.0016	0.00376	CcSEcCtD
Amantadine—Constipation—Ezetimibe—atherosclerosis	0.0016	0.00375	CcSEcCtD
Amantadine—Tachycardia—Niacin—atherosclerosis	0.00159	0.00375	CcSEcCtD
Amantadine—Pruritus—Rosuvastatin—atherosclerosis	0.00159	0.00374	CcSEcCtD
Amantadine—Skin disorder—Niacin—atherosclerosis	0.00159	0.00373	CcSEcCtD
Amantadine—Dyspnoea—Simvastatin—atherosclerosis	0.00159	0.00373	CcSEcCtD
Amantadine—Hyperhidrosis—Niacin—atherosclerosis	0.00158	0.00372	CcSEcCtD
Amantadine—Feeling abnormal—Lovastatin—atherosclerosis	0.00157	0.00369	CcSEcCtD
Amantadine—Dyspepsia—Simvastatin—atherosclerosis	0.00157	0.00369	CcSEcCtD
Amantadine—Anorexia—Niacin—atherosclerosis	0.00156	0.00366	CcSEcCtD
Amantadine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00156	0.00366	CcSEcCtD
Amantadine—Decreased appetite—Simvastatin—atherosclerosis	0.00155	0.00364	CcSEcCtD
Amantadine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00154	0.00362	CcSEcCtD
Amantadine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00154	0.00362	CcSEcCtD
Amantadine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00154	0.00361	CcSEcCtD
Amantadine—Fatigue—Simvastatin—atherosclerosis	0.00153	0.00361	CcSEcCtD
Amantadine—Anorexia—Pravastatin—atherosclerosis	0.00153	0.00361	CcSEcCtD
Amantadine—Hypotension—Niacin—atherosclerosis	0.00153	0.00359	CcSEcCtD
Amantadine—Constipation—Simvastatin—atherosclerosis	0.00152	0.00358	CcSEcCtD
Amantadine—Body temperature increased—Lovastatin—atherosclerosis	0.0015	0.00354	CcSEcCtD
Amantadine—Dizziness—Rosuvastatin—atherosclerosis	0.00148	0.00349	CcSEcCtD
Amantadine—Insomnia—Niacin—atherosclerosis	0.00148	0.00348	CcSEcCtD
Amantadine—Body temperature increased—Ezetimibe—atherosclerosis	0.00147	0.00347	CcSEcCtD
Amantadine—Paraesthesia—Niacin—atherosclerosis	0.00147	0.00345	CcSEcCtD
Amantadine—Feeling abnormal—Simvastatin—atherosclerosis	0.00147	0.00345	CcSEcCtD
Amantadine—Dyspnoea—Niacin—atherosclerosis	0.00146	0.00343	CcSEcCtD
Amantadine—Insomnia—Pravastatin—atherosclerosis	0.00145	0.00342	CcSEcCtD
Amantadine—Somnolence—Niacin—atherosclerosis	0.00145	0.00342	CcSEcCtD
Amantadine—Paraesthesia—Pravastatin—atherosclerosis	0.00144	0.0034	CcSEcCtD
Amantadine—Dyspepsia—Niacin—atherosclerosis	0.00144	0.00338	CcSEcCtD
Amantadine—Dyspnoea—Pravastatin—atherosclerosis	0.00143	0.00338	CcSEcCtD
Amantadine—Decreased appetite—Niacin—atherosclerosis	0.00142	0.00334	CcSEcCtD
Amantadine—Dyspepsia—Pravastatin—atherosclerosis	0.00142	0.00333	CcSEcCtD
Amantadine—Rash—Rosuvastatin—atherosclerosis	0.00142	0.00333	CcSEcCtD
Amantadine—Dermatitis—Rosuvastatin—atherosclerosis	0.00141	0.00333	CcSEcCtD
Amantadine—Gastrointestinal disorder—Niacin—atherosclerosis	0.00141	0.00332	CcSEcCtD
Amantadine—Body temperature increased—Simvastatin—atherosclerosis	0.00141	0.00331	CcSEcCtD
Amantadine—Headache—Rosuvastatin—atherosclerosis	0.00141	0.00331	CcSEcCtD
Amantadine—Hypersensitivity—Lovastatin—atherosclerosis	0.0014	0.0033	CcSEcCtD
Amantadine—Decreased appetite—Pravastatin—atherosclerosis	0.0014	0.00329	CcSEcCtD
Amantadine—Fatigue—Pravastatin—atherosclerosis	0.00139	0.00326	CcSEcCtD
Amantadine—Constipation—Pravastatin—atherosclerosis	0.00138	0.00324	CcSEcCtD
Amantadine—Hypersensitivity—Ezetimibe—atherosclerosis	0.00137	0.00324	CcSEcCtD
Amantadine—Asthenia—Lovastatin—atherosclerosis	0.00136	0.00321	CcSEcCtD
Amantadine—Pruritus—Lovastatin—atherosclerosis	0.00135	0.00317	CcSEcCtD
Amantadine—Asthenia—Ezetimibe—atherosclerosis	0.00134	0.00315	CcSEcCtD
Amantadine—Nausea—Rosuvastatin—atherosclerosis	0.00133	0.00314	CcSEcCtD
Amantadine—Feeling abnormal—Pravastatin—atherosclerosis	0.00133	0.00312	CcSEcCtD
Amantadine—Pruritus—Ezetimibe—atherosclerosis	0.00132	0.00311	CcSEcCtD
Amantadine—Hypersensitivity—Simvastatin—atherosclerosis	0.00131	0.00309	CcSEcCtD
Amantadine—Diarrhoea—Lovastatin—atherosclerosis	0.0013	0.00306	CcSEcCtD
Amantadine—Body temperature increased—Niacin—atherosclerosis	0.00129	0.00304	CcSEcCtD
Amantadine—Asthenia—Simvastatin—atherosclerosis	0.00128	0.003	CcSEcCtD
Amantadine—Diarrhoea—Ezetimibe—atherosclerosis	0.00128	0.003	CcSEcCtD
Amantadine—Body temperature increased—Pravastatin—atherosclerosis	0.00127	0.00299	CcSEcCtD
Amantadine—Pruritus—Simvastatin—atherosclerosis	0.00126	0.00296	CcSEcCtD
Amantadine—Dizziness—Lovastatin—atherosclerosis	0.00126	0.00296	CcSEcCtD
Amantadine—Dizziness—Ezetimibe—atherosclerosis	0.00123	0.0029	CcSEcCtD
Amantadine—Diarrhoea—Simvastatin—atherosclerosis	0.00122	0.00287	CcSEcCtD
Amantadine—Vomiting—Lovastatin—atherosclerosis	0.00121	0.00285	CcSEcCtD
Amantadine—Hypersensitivity—Niacin—atherosclerosis	0.0012	0.00283	CcSEcCtD
Amantadine—Rash—Lovastatin—atherosclerosis	0.0012	0.00282	CcSEcCtD
Amantadine—Dermatitis—Lovastatin—atherosclerosis	0.0012	0.00282	CcSEcCtD
Amantadine—Headache—Lovastatin—atherosclerosis	0.00119	0.0028	CcSEcCtD
Amantadine—Vomiting—Ezetimibe—atherosclerosis	0.00119	0.00279	CcSEcCtD
Amantadine—Hypersensitivity—Pravastatin—atherosclerosis	0.00119	0.00279	CcSEcCtD
Amantadine—Dizziness—Simvastatin—atherosclerosis	0.00118	0.00277	CcSEcCtD
Amantadine—Rash—Ezetimibe—atherosclerosis	0.00118	0.00277	CcSEcCtD
Amantadine—Dermatitis—Ezetimibe—atherosclerosis	0.00118	0.00277	CcSEcCtD
Amantadine—Asthenia—Niacin—atherosclerosis	0.00117	0.00276	CcSEcCtD
Amantadine—Headache—Ezetimibe—atherosclerosis	0.00117	0.00275	CcSEcCtD
Amantadine—Pruritus—Niacin—atherosclerosis	0.00116	0.00272	CcSEcCtD
Amantadine—Asthenia—Pravastatin—atherosclerosis	0.00115	0.00272	CcSEcCtD
Amantadine—Pruritus—Pravastatin—atherosclerosis	0.00114	0.00268	CcSEcCtD
Amantadine—Vomiting—Simvastatin—atherosclerosis	0.00113	0.00266	CcSEcCtD
Amantadine—Nausea—Lovastatin—atherosclerosis	0.00113	0.00266	CcSEcCtD
Amantadine—Rash—Simvastatin—atherosclerosis	0.00112	0.00264	CcSEcCtD
Amantadine—Dermatitis—Simvastatin—atherosclerosis	0.00112	0.00264	CcSEcCtD
Amantadine—Diarrhoea—Niacin—atherosclerosis	0.00112	0.00263	CcSEcCtD
Amantadine—Headache—Simvastatin—atherosclerosis	0.00111	0.00262	CcSEcCtD
Amantadine—Nausea—Ezetimibe—atherosclerosis	0.00111	0.00261	CcSEcCtD
Amantadine—Diarrhoea—Pravastatin—atherosclerosis	0.0011	0.00259	CcSEcCtD
Amantadine—Dizziness—Niacin—atherosclerosis	0.00108	0.00254	CcSEcCtD
Amantadine—Dizziness—Pravastatin—atherosclerosis	0.00106	0.0025	CcSEcCtD
Amantadine—Nausea—Simvastatin—atherosclerosis	0.00106	0.00249	CcSEcCtD
Amantadine—Vomiting—Niacin—atherosclerosis	0.00104	0.00244	CcSEcCtD
Amantadine—Rash—Niacin—atherosclerosis	0.00103	0.00242	CcSEcCtD
Amantadine—Dermatitis—Niacin—atherosclerosis	0.00103	0.00242	CcSEcCtD
Amantadine—Headache—Niacin—atherosclerosis	0.00102	0.00241	CcSEcCtD
Amantadine—Vomiting—Pravastatin—atherosclerosis	0.00102	0.00241	CcSEcCtD
Amantadine—Rash—Pravastatin—atherosclerosis	0.00101	0.00239	CcSEcCtD
Amantadine—Dermatitis—Pravastatin—atherosclerosis	0.00101	0.00238	CcSEcCtD
Amantadine—Headache—Pravastatin—atherosclerosis	0.00101	0.00237	CcSEcCtD
Amantadine—Nausea—Niacin—atherosclerosis	0.00097	0.00228	CcSEcCtD
Amantadine—Nausea—Pravastatin—atherosclerosis	0.000956	0.00225	CcSEcCtD
Amantadine—DRD2—GPCR ligand binding—F2—atherosclerosis	8.35e-05	0.000304	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—LPA—atherosclerosis	8.35e-05	0.000304	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTM1—atherosclerosis	8.33e-05	0.000304	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GHRL—atherosclerosis	8.32e-05	0.000303	CbGpPWpGaD
Amantadine—DDC—Metabolism—AGT—atherosclerosis	8.31e-05	0.000303	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PLA2G1B—atherosclerosis	8.26e-05	0.000301	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—PPARA—atherosclerosis	8.19e-05	0.000298	CbGpPWpGaD
Amantadine—MAOB—Metabolism—LPL—atherosclerosis	8.18e-05	0.000298	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LTA4H—atherosclerosis	8.17e-05	0.000297	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCG8—atherosclerosis	8.17e-05	0.000297	CbGpPWpGaD
Amantadine—DDC—Metabolism—APOE—atherosclerosis	8.15e-05	0.000297	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TNF—atherosclerosis	8.14e-05	0.000297	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—BGN—atherosclerosis	8.08e-05	0.000294	CbGpPWpGaD
Amantadine—DDC—Metabolism—CAV1—atherosclerosis	8.07e-05	0.000294	CbGpPWpGaD
Amantadine—DDC—Metabolism—APOA1—atherosclerosis	8.05e-05	0.000293	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOA4—atherosclerosis	8.05e-05	0.000293	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—CETP—atherosclerosis	8.01e-05	0.000292	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—APOA5—atherosclerosis	8e-05	0.000291	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALOX5—atherosclerosis	7.98e-05	0.000291	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPX1—atherosclerosis	7.98e-05	0.000291	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TNF—atherosclerosis	7.94e-05	0.000289	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CD36—atherosclerosis	7.77e-05	0.000283	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCR2—atherosclerosis	7.75e-05	0.000282	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EDNRA—atherosclerosis	7.75e-05	0.000282	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	7.73e-05	0.000282	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PLA2G1B—atherosclerosis	7.7e-05	0.000281	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—APOA1—atherosclerosis	7.68e-05	0.00028	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—PPARA—atherosclerosis	7.63e-05	0.000278	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GHRL—atherosclerosis	7.56e-05	0.000275	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCL2—atherosclerosis	7.45e-05	0.000271	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALOX5—atherosclerosis	7.44e-05	0.000271	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL4—atherosclerosis	7.41e-05	0.00027	CbGpPWpGaD
Amantadine—MAOB—Metabolism—MTHFR—atherosclerosis	7.37e-05	0.000268	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CG—atherosclerosis	7.35e-05	0.000268	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	7.32e-05	0.000267	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—KNG1—atherosclerosis	7.3e-05	0.000266	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AGTR1—atherosclerosis	7.26e-05	0.000264	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARA—atherosclerosis	7.23e-05	0.000263	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NAMPT—atherosclerosis	7.16e-05	0.000261	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—APOA1—atherosclerosis	7.16e-05	0.000261	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—LIPC—atherosclerosis	7.11e-05	0.000259	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPARG—atherosclerosis	7.1e-05	0.000258	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—APOC3—atherosclerosis	7.07e-05	0.000258	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	7.06e-05	0.000257	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—LDLR—atherosclerosis	7.03e-05	0.000256	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AGT—atherosclerosis	7e-05	0.000255	CbGpPWpGaD
Amantadine—DDC—Metabolism—INS—atherosclerosis	6.96e-05	0.000254	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOA2—atherosclerosis	6.93e-05	0.000252	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CETP—atherosclerosis	6.86e-05	0.00025	CbGpPWpGaD
Amantadine—MAOB—Metabolism—APOE—atherosclerosis	6.86e-05	0.00025	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CAV1—atherosclerosis	6.79e-05	0.000247	CbGpPWpGaD
Amantadine—MAOB—Metabolism—APOA1—atherosclerosis	6.78e-05	0.000247	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NAMPT—atherosclerosis	6.67e-05	0.000243	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KNG1—atherosclerosis	6.63e-05	0.000242	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—LIPC—atherosclerosis	6.63e-05	0.000242	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—UTS2—atherosclerosis	6.61e-05	0.000241	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AGTR1—atherosclerosis	6.59e-05	0.00024	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—APOC3—atherosclerosis	6.59e-05	0.00024	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SCARB1—atherosclerosis	6.57e-05	0.000239	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6—atherosclerosis	6.57e-05	0.000239	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—LDLR—atherosclerosis	6.55e-05	0.000239	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCG1—atherosclerosis	6.46e-05	0.000235	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6—atherosclerosis	6.4e-05	0.000233	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CETP—atherosclerosis	6.4e-05	0.000233	CbGpPWpGaD
Amantadine—DDC—Metabolism—ALB—atherosclerosis	6.38e-05	0.000232	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	6.36e-05	0.000232	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASR—atherosclerosis	6.34e-05	0.000231	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CX3CR1—atherosclerosis	6.34e-05	0.000231	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	6.25e-05	0.000228	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CX3CL1—atherosclerosis	6.21e-05	0.000226	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HMGCR—atherosclerosis	6.21e-05	0.000226	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CG—atherosclerosis	6.19e-05	0.000225	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—atherosclerosis	6.19e-05	0.000225	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—EDN1—atherosclerosis	6.15e-05	0.000224	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SCARB1—atherosclerosis	6.13e-05	0.000223	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CCL5—atherosclerosis	6.11e-05	0.000222	CbGpPWpGaD
Amantadine—DDC—Metabolism—NOS3—atherosclerosis	6.1e-05	0.000222	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ALB—atherosclerosis	6.08e-05	0.000222	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—FABP4—atherosclerosis	6.07e-05	0.000221	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LCAT—atherosclerosis	6.07e-05	0.000221	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—atherosclerosis	6.06e-05	0.000221	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	6e-05	0.000219	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARG—atherosclerosis	5.97e-05	0.000218	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOA4—atherosclerosis	5.96e-05	0.000217	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—atherosclerosis	5.91e-05	0.000215	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CNR2—atherosclerosis	5.89e-05	0.000215	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL8—atherosclerosis	5.89e-05	0.000214	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MMP3—atherosclerosis	5.88e-05	0.000214	CbGpPWpGaD
Amantadine—MAOB—Metabolism—INS—atherosclerosis	5.86e-05	0.000213	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP7A1—atherosclerosis	5.85e-05	0.000213	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PRKCG—atherosclerosis	5.81e-05	0.000212	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HMGCR—atherosclerosis	5.79e-05	0.000211	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	5.77e-05	0.00021	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ALB—atherosclerosis	5.67e-05	0.000207	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EDN1—atherosclerosis	5.59e-05	0.000204	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—atherosclerosis	5.58e-05	0.000203	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL5—atherosclerosis	5.55e-05	0.000202	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	5.54e-05	0.000202	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCA1—atherosclerosis	5.53e-05	0.000202	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	5.46e-05	0.000199	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP27A1—atherosclerosis	5.41e-05	0.000197	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ALB—atherosclerosis	5.37e-05	0.000196	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	5.3e-05	0.000193	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	5.3e-05	0.000193	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PRKCG—atherosclerosis	5.27e-05	0.000192	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VWF—atherosclerosis	5.25e-05	0.000191	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOC3—atherosclerosis	5.22e-05	0.00019	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LDLR—atherosclerosis	5.19e-05	0.000189	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCA1—atherosclerosis	5.16e-05	0.000188	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NOS3—atherosclerosis	5.14e-05	0.000187	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOA2—atherosclerosis	5.13e-05	0.000187	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLA2G2A—atherosclerosis	5.13e-05	0.000187	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALOX15—atherosclerosis	5.13e-05	0.000187	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALOX5AP—atherosclerosis	5.13e-05	0.000187	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AGT—atherosclerosis	5.11e-05	0.000186	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCG5—atherosclerosis	5.07e-05	0.000185	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL3—atherosclerosis	5.06e-05	0.000185	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	4.94e-05	0.00018	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LPA—atherosclerosis	4.89e-05	0.000178	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NCF1—atherosclerosis	4.85e-05	0.000177	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HMOX1—atherosclerosis	4.75e-05	0.000173	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BGN—atherosclerosis	4.74e-05	0.000173	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—F2—atherosclerosis	4.72e-05	0.000172	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—atherosclerosis	4.7e-05	0.000171	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOA5—atherosclerosis	4.69e-05	0.000171	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AGT—atherosclerosis	4.64e-05	0.000169	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EDNRA—atherosclerosis	4.58e-05	0.000167	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCR2—atherosclerosis	4.58e-05	0.000167	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CYBA—atherosclerosis	4.56e-05	0.000166	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—APOB—atherosclerosis	4.55e-05	0.000166	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	4.52e-05	0.000165	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLA2G1B—atherosclerosis	4.51e-05	0.000164	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	4.47e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PLAT—atherosclerosis	4.46e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PARP1—atherosclerosis	4.46e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GHRL—atherosclerosis	4.46e-05	0.000163	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HMOX1—atherosclerosis	4.42e-05	0.000161	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTM1—atherosclerosis	4.42e-05	0.000161	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALOX5—atherosclerosis	4.36e-05	0.000159	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—LPL—atherosclerosis	4.34e-05	0.000158	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—F2—atherosclerosis	4.29e-05	0.000156	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—APOB—atherosclerosis	4.24e-05	0.000154	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPX1—atherosclerosis	4.24e-05	0.000154	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	4.2e-05	0.000153	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CD36—atherosclerosis	4.12e-05	0.00015	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTM1—atherosclerosis	4.12e-05	0.00015	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	4.1e-05	0.000149	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—LPL—atherosclerosis	4.05e-05	0.000147	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPX1—atherosclerosis	3.95e-05	0.000144	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KNG1—atherosclerosis	3.92e-05	0.000143	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NAMPT—atherosclerosis	3.91e-05	0.000142	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MTHFR—atherosclerosis	3.91e-05	0.000142	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AGTR1—atherosclerosis	3.89e-05	0.000142	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LIPC—atherosclerosis	3.89e-05	0.000142	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOC3—atherosclerosis	3.86e-05	0.000141	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CD36—atherosclerosis	3.84e-05	0.00014	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LDLR—atherosclerosis	3.84e-05	0.00014	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARA—atherosclerosis	3.83e-05	0.00014	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL2—atherosclerosis	3.82e-05	0.000139	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PLG—atherosclerosis	3.8e-05	0.000138	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CETP—atherosclerosis	3.75e-05	0.000137	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AGT—atherosclerosis	3.71e-05	0.000135	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	3.68e-05	0.000134	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MTHFR—atherosclerosis	3.64e-05	0.000133	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—APOE—atherosclerosis	3.64e-05	0.000133	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CAV1—atherosclerosis	3.61e-05	0.000131	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—APOA1—atherosclerosis	3.6e-05	0.000131	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SOCS3—atherosclerosis	3.59e-05	0.000131	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SCARB1—atherosclerosis	3.59e-05	0.000131	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARA—atherosclerosis	3.57e-05	0.00013	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP3—atherosclerosis	3.47e-05	0.000126	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AGT—atherosclerosis	3.46e-05	0.000126	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF2—atherosclerosis	3.46e-05	0.000126	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—APOE—atherosclerosis	3.39e-05	0.000124	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HMGCR—atherosclerosis	3.39e-05	0.000124	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CAV1—atherosclerosis	3.36e-05	0.000122	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOB—atherosclerosis	3.36e-05	0.000122	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—APOA1—atherosclerosis	3.35e-05	0.000122	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	3.33e-05	0.000121	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	3.32e-05	0.000121	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EDN1—atherosclerosis	3.3e-05	0.00012	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CG—atherosclerosis	3.28e-05	0.00012	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL5—atherosclerosis	3.28e-05	0.000119	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LPL—atherosclerosis	3.2e-05	0.000117	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARG—atherosclerosis	3.17e-05	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKCG—atherosclerosis	3.11e-05	0.000113	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—INS—atherosclerosis	3.11e-05	0.000113	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CG—atherosclerosis	3.06e-05	0.000112	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SPP1—atherosclerosis	3.03e-05	0.000111	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCA1—atherosclerosis	3.02e-05	0.00011	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	3.02e-05	0.00011	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARG—atherosclerosis	2.95e-05	0.000108	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—INS—atherosclerosis	2.9e-05	0.000106	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALB—atherosclerosis	2.85e-05	0.000104	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFB—atherosclerosis	2.81e-05	0.000102	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—atherosclerosis	2.81e-05	0.000102	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AGT—atherosclerosis	2.74e-05	9.98e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NOS3—atherosclerosis	2.73e-05	9.93e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LEP—atherosclerosis	2.69e-05	9.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOE—atherosclerosis	2.69e-05	9.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CAV1—atherosclerosis	2.66e-05	9.69e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALB—atherosclerosis	2.66e-05	9.68e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOA1—atherosclerosis	2.65e-05	9.67e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HMOX1—atherosclerosis	2.59e-05	9.45e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—atherosclerosis	2.56e-05	9.34e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NOS3—atherosclerosis	2.54e-05	9.26e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—F2—atherosclerosis	2.53e-05	9.22e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—atherosclerosis	2.49e-05	9.08e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOB—atherosclerosis	2.48e-05	9.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	2.42e-05	8.83e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTM1—atherosclerosis	2.42e-05	8.8e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LPL—atherosclerosis	2.37e-05	8.64e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—atherosclerosis	2.36e-05	8.6e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—atherosclerosis	2.32e-05	8.47e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	2.32e-05	8.45e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPX1—atherosclerosis	2.31e-05	8.43e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—INS—atherosclerosis	2.29e-05	8.36e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL2—atherosclerosis	2.26e-05	8.22e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CD36—atherosclerosis	2.25e-05	8.21e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1—atherosclerosis	2.22e-05	8.08e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTHFR—atherosclerosis	2.14e-05	7.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	2.11e-05	7.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARA—atherosclerosis	2.09e-05	7.63e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AGT—atherosclerosis	2.03e-05	7.39e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOS3—atherosclerosis	2.01e-05	7.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOE—atherosclerosis	1.99e-05	7.24e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CAV1—atherosclerosis	1.97e-05	7.17e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOA1—atherosclerosis	1.97e-05	7.16e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.79e-05	6.54e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.78e-05	6.5e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARG—atherosclerosis	1.73e-05	6.31e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.72e-05	6.28e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—INS—atherosclerosis	1.7e-05	6.19e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.7e-05	6.18e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.61e-05	5.88e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.6e-05	5.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.57e-05	5.72e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.57e-05	5.7e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALB—atherosclerosis	1.56e-05	5.67e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NOS3—atherosclerosis	1.49e-05	5.43e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.45e-05	5.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.44e-05	5.23e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.37e-05	4.99e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—atherosclerosis	1.36e-05	4.96e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.33e-05	4.85e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—atherosclerosis	1.25e-05	4.56e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—atherosclerosis	1.17e-05	4.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—atherosclerosis	1e-05	3.65e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—atherosclerosis	9.25e-06	3.37e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—atherosclerosis	6.85e-06	2.49e-05	CbGpPWpGaD
